1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow Tuberous Sclerosis 2: new trials by email Literature Review of Tuberous Sclerosis 2 trials Research Report on Tuberous Sclerosis 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Everolimus (RAD001), Everolimus Placebo - Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM) | Phase 3 | Completed | Novartis Pharmaceuticals | 118 | 2009-04-01 | 2017-02-17 |
Angiomyolipoma (1) · Astrocytoma (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Lymphangioleiomyomatosis (1) · Seizures (1) · Tuberous Sclerosis (1)
Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Glioma (1) · Hamartoma (1) · Hemic and Lymphatic Diseases (1) · Heredodegenerative Disorders, Nervous System (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphangiomyoma (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Malformations of Cortical Development (1) · Malformations of Cortical Development, Group I (1) · Neoplasm, Lymphatic Tissue (1)
Everolimus (1)
Canada (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Netherlands (1) · Poland (1) · Russia (1) · Spain (1) · United Kingdom (1) · United States (1)
PMID 26156073, PMID 29023494, PMID 30053159, PMID 30192751
2008 (1)